Our Story
OUR DNA
LNC Therapeutics is working on the first gut microbiota directed drugs initiated by medical nutrition product clinical outcomes
Obesity management to date
+ learn moreThree therapeutic strategies currently predominate with respect to obesity management: nutritional approaches, drugs and bariatric surgery.
Despite the results obtained, they all have limitations: low level of credibility, safety issues, moderate efficacy, no fat loss specificity, weight regain phenomenon, underlying causes not addressed.
FAT LOSS SPECIFICITY
It is well established that lean mass preservation is a long-term maintenance factor on weight and metabolism.
We cannot evaluate efficacy of therapeutic strategy only on weight loss. Considering the preservation of lean body mass and so the fat mass specificity is a mandatory.
go back to the site
From the creation of LNC Therapeutics, the founders, previously managers in the pharmaceutical industry, shared the same vision:
to address the issue of obesity and cardiometabolic disorders
by acting on its root causes
Thanks to this ambition and by implementing a truly patient- focused approach, LNC Therapeutics was able to develop and clinically assess a medical nutrition product called Stablor between 2011 and 2015.
why medical nutrition ?
Obesity is a multicomponent disease and overweight/obese patient have specific metabolic impairments and nutritional deficiencies.
The deep understanding of the physiopathology leads LNC Therapeutics to develop Medical Food: Only Medical Food have the capability to address underlying causes instead of consequences of the disease with a safe and efficient profile.
go back to the site
The same four-year period saw major growth in research on the impact of the microbiota on health (4,500 publications in PubMed versus 635 in 2005-2009).
PHYSIOPATHOLOGY OF OVERWEIGHT/OBESE PATIENT PRESENTING ABDOMINAL OBESITY AND ASSOCIATED RISK FACTORS.
Inadequate lifestyle = Sedentarity, poor diet (quality+quantity), genetic
GUT IMPAIRMENTS
- Microbiome dysbiosis
- Gut permeability
- Inflammation
CHRONIC METABOLIC IMPAIRMENTS AND NUTRITIONAL DEFICIENCES
- Inflammation
- Insulin-resistance
- Lipid metabolism dysregulation (dyslipidemia)
- Nutrients deficiencies
go back to the site
The close collaboration that has developed LNC Therapeutics with the international research community led the company to look more closely at this promising field.
Intestinal microbiota plays a vital role in obesity.
Thus in 2014, LNC Therapeutics initiated an ancillary study to the international clinical trial being carried out on Stablor. It was designed to determine the impact of this product on the human microbiota.
In order to be on the cutting edge of scientific research and innovation, we select and analyse key scientific publications and materials
Discover our selection
Find out more